The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Real-world study on efficacy and safety of ide-cel in older patients with RRMM
|
Data from a real-world study on the efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM) were published in Blood Advances by Kalariya et al.1 The study included safety and efficacy data from older patients (≥65 years) who were ineligible for the KarMMa study (NCT03361748). |
| Key learnings: |
|
Overall, 156 patients were included, of which 81 were aged <65 years and 75 were aged ≥65 years. Among the older patients, 66.7% were frail and 77.3% did not meet the eligibility criteria for the KarMMa study. |
|
The best overall response rate (ORR) and complete response rate with ide-cel were comparable among both older and younger patients (86.7% vs 84% and 56% vs 54.3%, respectively). |
|
A numerically higher median progression-free survival (PFS) and overall survival (OS) was observed among older patients.
|
|
The incidences of any grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were higher in older patients. However, the incidences of Grade ≥3 CRS and ICANS were comparable between older and younger patients. CRS:
ICANS:
|
|
Despite the higher prevalence of frailty and geriatric characteristics, such as polypharmacy, comorbidities, and organ dysfunction, the efficacy and safety data of ide-cel in older patients were comparable to younger patients. |
|
The data highlighted the feasibility of ide-cel in older patients with RRMM, and the potential for broader adoption in clinical practice. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content